EGFR and neoplasm: The tumor response of patients with different EGFR mutations is shown in Fig. 4. In addition, in the survival analysis, for acquired resistance, we found that patients who bore acquired Thr790Met or less than three organ metastases showed distinctly longer survival (mPFS 7.9 months, mOS 23.1 months vs. mPFS 4.6 months, mOS 11.3 months; mPFS 9.2 months, mOS 28.3 months vs. mPFS 5.0 months, mOS 11.6 months) (p value < 0.05) (Fig. 3C, D; Fig. 3E, F).